392 related articles for article (PubMed ID: 18721002)
1. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
Padhi D; Salfi M; Emery M
Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
[TBL] [Abstract][Full Text] [Related]
2. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
[TBL] [Abstract][Full Text] [Related]
3. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
[TBL] [Abstract][Full Text] [Related]
4. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
5. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole.
Harris RZ; Salfi M; Sullivan JT; Padhi D
Clin Pharmacokinet; 2007; 46(6):495-501. PubMed ID: 17518508
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
[TBL] [Abstract][Full Text] [Related]
8. Microdosed midazolam for the determination of cytochrome P450 3A activity: Development and clinical evaluation of a buccal film.
Kiene K; Hayasi N; Burhenne J; Uchitomi R; Sünderhauf C; Schmid Y; Haschke M; Haefeli WE; Krähenbühl S; Mikus G; Inada H; Huwyler J
Eur J Pharm Sci; 2019 Jul; 135():77-82. PubMed ID: 31102650
[TBL] [Abstract][Full Text] [Related]
9. Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males.
Toyama K; Furuie H; Kuroda K; Ishizuka T; Okuda Y; Shimizu T; Kato M; Igawa Y; Nishikawa Y; Ishizuka H
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):685-694. PubMed ID: 34383278
[TBL] [Abstract][Full Text] [Related]
10. Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects.
Wong SL; Goldberg MR; Ballow CH; Kitt MM; Barriere SL
Pharmacotherapy; 2010 Feb; 30(2):136-43. PubMed ID: 20099988
[TBL] [Abstract][Full Text] [Related]
11. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.
Krupka E; Venisse N; Lafay C; Gendre D; Diquet B; Bouquet S; Perault MC
Eur J Clin Pharmacol; 2006 Aug; 62(8):653-9. PubMed ID: 16832678
[TBL] [Abstract][Full Text] [Related]
12. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
[TBL] [Abstract][Full Text] [Related]
14. Effects of Grapefruit and Pomegranate Juices on the Pharmacokinetic Properties of Dapoxetine and Midazolam in Healthy Subjects.
Abdlekawy KS; Donia AM; Elbarbry F
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):397-405. PubMed ID: 27294349
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin.
Padhi D; Sullivan JT
Drugs R D; 2007; 8(2):79-87. PubMed ID: 17324005
[TBL] [Abstract][Full Text] [Related]
16. The effect of ticagrelor on the metabolism of midazolam in healthy volunteers.
Teng R; Butler K
Clin Ther; 2013 Jul; 35(7):1025-37. PubMed ID: 23870610
[TBL] [Abstract][Full Text] [Related]
17. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
Gupta P; Alvey C; Wang R; Dowty ME; Fahmi OA; Walsky RL; Riese RJ; Krishnaswami S
Br J Clin Pharmacol; 2012 Jul; 74(1):109-15. PubMed ID: 22233204
[TBL] [Abstract][Full Text] [Related]
18. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
Backman JT; Kivistö KT; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Mar; 54(1):53-8. PubMed ID: 9591931
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study.
Lee S; Gu N; Kim BH; Lim KS; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 May; 34(5):1160-9. PubMed ID: 22503212
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals.
Padhi D; Salfi M; Harris RZ
Am J Ther; 2007; 14(3):235-40. PubMed ID: 17515696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]